MirZyme Appoints Lindsey Carnett as U.S. Global Ambassador for Women’s Health Innovation

MirZyme Therapeutics, a UK-based biotechnology company focused on transforming maternal health, today announced the appointment of Lindsey Carnett, CEO and President of Marketing Maven Public Relations, Inc., as Global Ambassador for Women’s Health Innovation in the United States.

In this role, Carnett will support MirZyme’s mission to make preeclampsia predictable and

treatable through strategic introductions, advocacy, and engagement with healthcare

institutions, women’s health and heart organisations across the United States.

This appointment marks a key step in MirZyme’s expansion into the United States, engaging with hospitals, investors, and national organisations to advance maternal health innovation.

Preeclampsia is one of the leading causes of maternal and perinatal morbidity and mortality worldwide. MirZyme is developing a precision maternal vascular medicine platform combining diagnostics and therapeutics, designed to identify women at risk and treat the disease before severe complications develop.

Carnett brings extensive experience in healthcare communications, strategic partnerships, and network development across the healthcare ecosystem.

Through her role as Global Ambassador, she will support:

• Engagement with hospitals and maternal health networks

• Strategic relationships with women’s health organisations

• Connections with healthcare innovation partners

• Awareness initiatives focused on preeclampsia and maternal vascular health

Professor Asif Ahmed, Founder and CEO of MirZyme Therapeutics, said:

“Preeclampsia remains one of the leading causes of maternal and perinatal morbidity and mortality worldwide. Lindsey’s experience and network within the U.S. healthcare ecosystem will help us accelerate awareness, partnerships, and investment as we advance our mission to make preeclampsia predictable and preventable.”

Lindsey Carnett, MirZyme U.S. Global Ambassador for Women’s Health Innovation

commented:

“Maternal health remains one of the most important and under-addressed challenges in

healthcare. Through my work with American Cancer Society, American Heart Association

and Go Red for Women, WaterAid and other healthcare organisations, I have been exposed to significant education from leading cardiologists, gynaecologists, oncologists, nutritionists regarding the health complications that unfold later in life if women do not get adequate care early in their lives, ahead of pregnancy, perimenopause and menopause. As a mother and friend to women who have experienced preeclampsia, I am excited to support MirZyme’s mission to improve outcomes for mothers and babies in my country and the world.”

MirZyme’s platform integrates diagnostic tools and novel oral therapies designed to address the underlying vascular causes of preeclampsia.

The company’s guiding mission is simple:

One Test. One Pill. Save Two Lives.

For media inquiries, please get in touch:

...

MirZyme Therapeutics is a precision medicine platform company focused on predicting

and treating preeclampsia. Its integrated approach combines the M-PREG® diagnostic

platform, which identifies women at risk, helps guide treatment with MZe786, and can

monitor treatment effectiveness, with MZe786, a first-in-class oral therapeutic targeting

the underlying vascular pathology of the disease. This closed-loop model enables earlier

intervention, more personalised care, and improved outcomes for both mother and

baby. MirZyme has been recognised by the U.S. ARPA-H Investor Catalyst Hub and continues to build global partnerships in maternal health.

One Test. One Pill. Save Two Lives.